● FCUV shares gained roughly 17% amid a wild stretch that at one point saw the stock explode from under $2 toward an intraday peak near $21 before settling far lower.
● NEXR shares surged 13.92% without a clearly verifiable, company-specific catalyst, extending a pattern of thin-liquidity spikes and fades.
● CABO shares rose about 15% in a single session, clawing back a portion of losses that had left the stock down roughly 60% year to date.
● GAME shares rose about 15% after second-quarterRevenueclimbed 137% year over year to $18.5 million, with record adjusted EBITDA of about $1.0 million.
● HCWB shares rose 12.55% after the company's second-quarter update on HCW9302, showing all three patients in a second dose cohort achieved at least a 25% reduction in SALT scores for alopecia areata.
● Picard Medical shares surged roughly 86% after second-quarter 2026Revenueof about $2.95 million nearly doubled the consensus estimate near $1.55 million.
● APLM shares climbed 14.68% in a sharp countertrend bounce after a prolonged decline driven by the company's small scale and dilution risk.
● CUE shares gained roughly 15%, extending a striking year as the company broadens its pipeline beyond its original oncology roots.
● IFRX shares rocketed 20% without a clearly identifiable, same-day company-specific catalyst, characteristic of a small-cap biotech with a modest float.
● PRME shares climbed 14.15% amid a broadly firmer tape for advanced-therapy names, without a single Prime-specific disclosure behind the move.